Celcuity To Participate in Upcoming Investor Conferences

Rhea-AI Summary

Celcuity (Nasdaq: CELC) announced CEO and co-founder Brian Sullivan will present and hold investor meetings at three investor conferences in March 2026. Presentations include a fireside chat at the TD Cowen Healthcare Conference on March 4, 2026 and at the Leerink Global Healthcare Conference on March 10, 2026, plus investor meetings at Jefferies Biotech on the Beach on March 11, 2026.

Live webcasts will be available via provided summitcast links and the company’s Investors page, with replays posted shortly after each live event.

MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

• A fireside chat at the TD Cowen 46^th Annual Healthcare Conference at 10:30 a.m. ET on Wednesday, March 4, 2026. A live webcast will be available using this weblink: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/NYER3h287L9qyxak8BZiq2
• A fireside chat at the Leerink Global Healthcare Conference at 2:20 p.m. ET on Tuesday, March 10, 2026. A live webcast will be available using this weblink: https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/VziaefXK3xAkvtByRaxLpT

• Jefferies Biotech on the Beach Summit; Wednesday, March 11, 2026. Management will host one-on-one investor meetings only.
  

Alternatively, the live webcasts will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live events.

About Celcuity

Celcuity is a clinical-stage biotechnology company pursuing the development of targeted therapies for the treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer (“ABC”), has completed enrollment, and the company has reported detailed results for the PIK3CA wild-type cohort. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- ABC, is ongoing. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com  
(763) 392-0123  
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924

FAQ

When will Celcuity (CELC) present at the TD Cowen Healthcare Conference in 2026?

Celcuity will present at 10:30 a.m. ET on March 4, 2026. According to the company, CEO Brian Sullivan will appear in a fireside chat and a live webcast will be available via the provided summitcast link.

How can investors watch Celcuity (CELC) at the Leerink Global Healthcare Conference on March 10, 2026?

Investors can watch the fireside chat at 2:20 p.m. ET on March 10, 2026 via a live webcast. According to the company, the webcast link and a replay will also be posted on the Celcuity Investors events page.

What Celcuity (CELC) activities are scheduled at Jefferies Biotech on the Beach on March 11, 2026?

Management will host one-on-one investor meetings only on March 11, 2026. According to the company, there will be no public stage presentation, but management meetings are scheduled and webcasts for other events remain available.

Where will Celcuity (CELC) post webcasts and replays for its March 2026 investor events?

Webcasts and replays will be posted on the company’s Investors page at https://ir.celcuity.com/events-presentations/. According to the company, live streams use summitcast links and replays will be available shortly after each live event.

Who will represent Celcuity (CELC) at the March 2026 investor conferences?

Brian Sullivan, CEO and co-founder, will present and meet with investors at the March 2026 events. According to the company, Sullivan will lead the fireside chats and management will host one-on-one meetings at Jefferies Biotech on the Beach.